Impact of pretransplant donor‐specific antibodies on kidney allograft recipients with negative flow cytometry cross‐matches. Issue 6 (3rd June 2018)

• Record Type: Journal Article
• Authors: Kwon, Hyunwook; Kim, Young Hoon; Choi, Ji Yoon; Shin, Sung; Jung, Joo Hee; Park, Su‐Kil; Han, Duck Jong
• Is Part Of: Clinical transplantation. Volume 32:Issue 6(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-06-03
• Subjects: alloantibody -- graft rejection -- kidney transplantation; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ctr.13266
• Languages: English
• ISSNs: 0902-0063

Abstract

Abstract: The Luminex test can detect low levels of donor‐specific antibody (DSA) that cannot be detected by flow‐cytometric cross‐matching (FCXM) in kidney transplantation (KT). This study evaluated the impact of DSA on clinical outcomes in KT recipients negative on FCXM. Of 575 consecutive patients who underwent living donor KT between January 2013 and July 2016, 494 (85.9%) were DSA‐negative and 81 (14.1%) were DSA‐positive. Although rates of acute cellular rejection (ACR) at 1 year were similar in the 2 groups ( P = .54), the incidence of antibody‐mediated rejection (ABMR) was significantly higher in the DSA‐positive group ( P < .01). There was no statistically significant association between rejection‐free graft survival (RFGS) rates and pretransplant class I DSA. However, evaluation of pretransplant class II DSA showed that RFGS rates were significantly lower in patients with mean fluorescence intensity (MFI) >3000 than in patients with DSA‐negative ( P < .01). On multivariate analyses, class II DSA MFI ≥5000 was a significant risk factor for acute rejection (hazard ratio, 7.48; P < .01). These findings suggested that pretransplant DSA alone did not affect graft survival in KT recipients without desensitization. However, class II DSA MFI >5000 was an independent predictor of acute rejection in DSA‐positive patients.